Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Biomarker-Oriented Therapy in Bladder and Renal Cancer.

International journal of molecular sciences - 11 Mar 2021

Scholtes Mathijs P, Alberts Arnout R, Iflé Iris G, Verhagen Paul C M S, van der Veldt Astrid A M, Zuiverloon Tahlita C M

Abstract excerpt

Treatment of patients with urothelial carcinoma (UC) of the bladder or renal cancer has changed significantly during recent years and efforts towards biomarker-directed therapy are being investigated. Immune checkpoint inhibition (ICI) or fibroblast growth factor receptor (FGFR) directed therapy are being evaluated for non-muscle invasive bladder cancer (NMIBC) patients, as well as muscle-invasive bladder cancer...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to B7-H1 Antigen
Share to Carcinoma, Renal Cell

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cisplatin

Share to Immune Checkpoint Inhibitors

Share to Pyrazoles

Share to Quinoxalines

Share to Receptor, Fibroblast Growth Factor, Type 2

Share to Receptor, Fibroblast Growth Factor, Type 3

Source

Open in PubMed Open full text

Identifiers

PMID: 33799514
DOI: 10.3390/ijms22062832
PMCID: PMC7999814

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Biomarker-Oriented Therapy in Bladder and Renal Cancer.PMID 33799514Read ↗

New and promising strategies in the management of bladder cancer.Semantic proximity Read ↗

Novel Molecular Biomarkers to Guide Treatment Decision-making in Metastatic Urothelial Cancer-A Patient Cohort Analysis.Semantic proximity Read ↗

Precision medicine for urothelial bladder cancer: update on tumour genomics and immunotherapy.Semantic proximity Read ↗

Advances in immunotherapy for bladder cancer and clinical practice of next-generation sequencing.Semantic proximity Read ↗

Emerging therapeutic targets in bladder cancer.Semantic proximity Read ↗

Management of advanced bladder cancer in the era of targeted therapies.Semantic proximity Read ↗

Integrated molecular and pharmacological characterization of patient-derived xenografts from bladder and ureteral cancers identifies new potential therapiesSemantic proximity Read ↗

Novel biomarkers in bladder cancer.Semantic proximity Read ↗

Defining biologically directed therapy target signatures in urothelial carcinoma: A transcriptomic framework for precision therapySemantic proximity Read ↗

Novel molecular biomarkers to guide treatment-decision making in metastatic urothelial cancer - A patient cohort analysisSemantic proximity Read ↗

Molecularly Targeted Therapy towards Genetic Alterations in Advanced Bladder CancerSemantic proximity Read ↗

Beyond conventional chemotherapy: Emerging molecular targeted and immunotherapy strategies in urothelial carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.